Trial reportCold Spring Harbor molecular case studies2019
Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with
Open access · diamondAbstract readClinical Trial, Phase II
In one paragraph
Trial report in Cold Spring Harbor molecular case studies, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- The E3 ubiquitin ligase HUWE1 is required for KRAS-induced lung cancer.Cell death & disease · 2026Article
- Interleukin-1β as target to induce synthetic lethality in KRAS mutant biliary tract cancer.Clinical and molecular hepatology · 2026Article
- Targeting proteostasis for cancer therapy: current advances, challenges, and future perspectives.Molecular cancer · 2025Review
- [Research and Therapeutic Advances of 26S Proteasome Subunit in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Synthetic lethal strategies for the development of cancer therapeutics.Nature reviews. Clinical oncology · 2025Review
- Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.Cancer gene therapy · 2024Review
- Proteasome inhibitors in the treatment of nonsmall cell lung cancer: A systematic review of clinical evidence.Health science reports · 2023Article
- Targeting KRAS in Colorectal Cancer: A Bench to Bedside Review.International journal of molecular sciences · 2023Review
- Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient.Frontiers in oncology · 2023Article
- Synthetic Vulnerabilities in the KRAS Pathway.Cancers · 2022Review
- Syrbactin-class dual constitutive- and immuno-proteasome inhibitor TIR-199 impedes myeloma-mediated bone degeneration in vivo.Bioscience reports · 2022Article
- Genomic characteristics of invasive mucinous adenocarcinoma of the lung with multiple pulmonary sites of involvement.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2022Article
- NF-κB signaling in inflammation and cancer.MedComm · 2021Review
- Transition From Distinct Types of KRAS Mutation-Harboring Multifocal Lung Adenocarcinoma to Rhabdoid Tumor: A Longitudinal Follow-Up.The American journal of case reports · 2021Article
- Current approach and novel perspectives in nasopharyngeal carcinoma: the role of targeting proteasome dysregulation as a molecular landmark in nasopharyngeal cancer.Journal of experimental & clinical cancer research : CR · 2021Review
- The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures.Frontiers in oncology · 2021Review
- Development of a miniaturized 3D organoid culture platform for ultra-high-throughput screening.Journal of molecular cell biology · 2020Article
- TargetingInternational journal of molecular sciences · 2020Review
- Drug Development Targeting the Ubiquitin-Proteasome System (UPS) for the Treatment of Human Cancers.Cancers · 2020Review
- Harnessing the vulnerabilities of p53 mutants in lung cancer - Focusing on the proteasome: a new trick for an old foe?Cancer biology & therapy · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Alexander Drilon *Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Adam J Schoenfeld *Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Kathryn C ArbourThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Anna LitvakThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Ai NiDepartment of Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Joseph MontecalvoDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Helena A YuThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Elizabeth PanoraThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Linda AhnThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Maureen KennedyThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Anne Haughney-SillerThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Vincent MillerThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Michelle GinsbergDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Marc LadanyiDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Maria ArcilaDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Natasha RekhtmanDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Mark G KrisThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Gregory J RielyThoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Memorial Sloan Kettering Cancer Center · USCornell University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MNCI NIH HHS P30 CA008748
Abstract
PubMed holds no abstract for this paper.
Indexed as
Adenocarcinoma, MucinousAdultAgedAged, 80 and overAntineoplastic AgentsBortezomibCarcinoma, Non-Small-Cell LungFemaleHumansInjections, SubcutaneousLung NeoplasmsMaleMiddle AgedMutationProspective StudiesProto-Oncogene Proteins p21(ras)Antineoplastic AgentsBortezomibKRAS protein, humanProto-Oncogene Proteins p21(ras)lung adenocarcinoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.